Literature DB >> 21708513

[Ovarian yolk sac tumour: general review].

Caroline Even1, Catherine Lhommé, Pierre Duvillard, Philippe Morice, Corinne Balleyguier, Patricia Pautier, Frédéric Troalen, Thibault de La Motte Rouge.   

Abstract

Ovarian yolk sac tumour (OYST) is a very rare malignancy arising most often in young women. Preoperative clinical, biological (alpha-foetoprotein) and radiological findings should help to establish the diagnosis of OYST, in order to propose adequate surgical treatment. The aim of surgery is to remove the primary tumour, to obtain an accurate histological diagnosis and to assess the disease extent. In young women, fertility-sparing surgery should be performed, in order to preserve the possibility of pregnancy later on. Chemotherapy has substantially modified the prognosis of these tumours, and practically all patients will be cured. The overall 5-year survival rate is 94% when patients are treated with BEP chemotherapy. Depending on the clinical situation, two to four cycles of the BEP regimen should be administered after surgery. Identification of prognostic factors may help to propose risk-adapted treatment in order to increase the cure rate in patients with a poor prognosis and to decrease toxicity in patients with a low risk of relapse. Fertility preservation represents a major objective in women treated for OYSTs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21708513     DOI: 10.1684/bdc.2011.1387

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

1.  Pregnancy and Delivery After Ovarian Yolk Sac Tumor: A Case Report.

Authors:  Mo'ath M Alrjoub; Amer Sindiani; Ola Alshriedeh; Zouhair Amarin
Journal:  Am J Case Rep       Date:  2021-08-19

2.  Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model.

Authors:  Manling Luo; Yuanqiao He; Baogang Xie; Shiyun Li; Fuqiang Gan; Shouhua Zhang; Puying Luo
Journal:  Pediatr Surg Int       Date:  2021-05-24       Impact factor: 1.827

3.  Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells.

Authors:  Yun He; Yang Bi; Yi Hua; Dongyao Liu; Sheng Wen; Qiang Wang; Mingyong Li; Jing Zhu; Tao Lin; Dawei He; Xuliang Li; Zhigang Wang; Guanghui Wei
Journal:  J Exp Clin Cancer Res       Date:  2011-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.